TG Therapeutics (TGTX) Plans Conf. Call for GENUINE Phase 3 Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Crude Inventory Rose 2.7 Million Barrels Last Week, Says EIA
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
TG Therapeutics (TGTX) Shares Move Up from Lows Amid Amended GENUINE Phase 3 Protocol
October 13, 2016 7:24 AM EDTTG Therapeutics (Nasdaq: TGTX) shares are seeing a slight rebound Thursday morning after the company announced an amended protocol for its GENUINE Phase 3 trial. The stock is down around 4 percent, but was 22 percent lower Wednesday night.
For more on the updated protocol, click here.
... MoreTG Therapeutics (TGTX) Files Amended Protocol for GENUINE Phase 3 Trial; Revises Primary Endpoint
October 13, 2016 7:02 AM EDTTG Therapeutics, Inc. (Nasdaq : TGTX) announced that it has filed with the FDA an amended protocol for the GENUINE Phase 3 trial. Prior to the amendments, the GENUINE study consisted of two parts:
Part I to evaluate the effect of the addition of TG-1101 to ibrutinib on overall response rate (ORR) in approximately the first 200 patients enrolled, to support a filing for accelerated approval of TG-1101; andPart II to evaluate the effect of the addition of TG-1101 to ibrutinib on progression-free survival (PFS) in all study patients (approximately 330), to... More
